🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Christopher G. Nasveschuk

C4 Therapeutics (United States)

ORCID: 0000-0003-4671-6939

Biochemistry, Genetics and Molecular BiologyMedicineChemistry

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Preclinical Development of the Class-I–Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors”.

Preclinical Development of the Class-I–Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors

Molecular Cancer Therapeutics(2021)10.1158/1535-7163.mct-21-0455

N/A

0.489DataRank · unranked

25 citations

Todd M. Pitts, Dana Ungermannova, Christopher G. Nasveschuk, Gan Zhang, Andrew J. Phillips +15 more

Data from Preclinical Development of the Class-I–Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors

(2023)10.1158/1535-7163.c.6543273.v1

N/A

0DataRank · unranked

0 citations

Todd M. Pitts, Dana Ungermannova, Christopher G. Nasveschuk, Gan Zhang, Andrew J. K. Phillips +15 more

Data from Preclinical Development of the Class-I–Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors

(2023)10.1158/1535-7163.c.6543273

N/A

0DataRank · unranked

0 citations

Todd M. Pitts, Dana Ungermannova, Christopher G. Nasveschuk, Gan Zhang, Andrew J. K. Phillips +15 more